- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
ImmunityBio Hit with Class Action Lawsuit
Bragar Eagel & Squire files suit on behalf of investors who purchased shares between January and March 2026
Mar. 30, 2026 at 9:45pm
Got story updates? Submit your updates here. ›
The class action lawsuit against ImmunityBio alleges the company misled investors about its cancer therapy capabilities.NYC TodayBragar Eagel & Squire, P.C., a national stockholder rights law firm, has filed a class action lawsuit against ImmunityBio, Inc. (NASDAQ:IBRX) in the U.S. District Court for the Central District of California. The lawsuit alleges that ImmunityBio and its executives made false and misleading statements about the capabilities of the company's Anktiva product during the class period of January 19, 2026 to March 24, 2026, resulting in investor losses.
Why it matters
The lawsuit against ImmunityBio is the latest in a series of legal challenges facing the biotech company, which has been under scrutiny for its claims about its experimental cancer therapies. The outcome of this case could have significant financial and reputational implications for ImmunityBio.
The details
According to the lawsuit, ImmunityBio and its executives, including CEO Patrick Soon-Shiong, allegedly made false and misleading statements about the capabilities of Anktiva, the company's lead immunotherapy candidate. The lawsuit claims these statements inflated the company's stock price, and when the truth came to light, investors suffered losses.
- The class period for the lawsuit is January 19, 2026 to March 24, 2026.
- Investors have until May 26, 2026 to apply to the court to be appointed as lead plaintiff in the case.
The players
ImmunityBio, Inc.
A biopharmaceutical company focused on developing innovative therapies for cancer and infectious diseases.
Patrick Soon-Shiong
The founder, chairman, and CEO of ImmunityBio.
Bragar Eagel & Squire, P.C.
A nationally recognized stockholder rights law firm representing individual and institutional investors in securities, derivative, and commercial litigation.
What they’re saying
“If you purchased or acquired ImmunityBio securities between January 19, 2026 and March 24, 2026 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.”
— Brandon Walker, Partner, Bragar Eagel & Squire
What’s next
Investors have until May 26, 2026 to apply to the court to be appointed as lead plaintiff in the lawsuit.
The takeaway
The class action lawsuit against ImmunityBio highlights the ongoing scrutiny and legal challenges facing the company over its claims about its experimental cancer therapies. The outcome of this case could have significant financial and reputational implications for the biotech firm.
